These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28277814)

  • 1. The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies.
    Özcan P; Fiçicioğlu C; Ateş S; Can MG; Kaspar Ç; Akçin O; Yesiladali M
    Gynecol Endocrinol; 2017 Jun; 33(6):467-471. PubMed ID: 28277814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis.
    Ficicioglu C; Cenksoy PO; Yildirim G; Kaspar C
    Gynecol Endocrinol; 2014 May; 30(5):372-6. PubMed ID: 24576292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles.
    Tolikas A; Tsakos E; Gerou S; Prapas Y; Loufopoulos A
    Hum Fertil (Camb); 2011 Dec; 14(4):246-53. PubMed ID: 22088130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
    Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian response prediction in controlled ovarian stimulation for IVF using anti-Müllerian hormone in Chinese women: A retrospective cohort study.
    Zheng H; Chen S; Du H; Ling J; Wu Y; Liu H; Liu J
    Medicine (Baltimore); 2017 Mar; 96(13):e6495. PubMed ID: 28353597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
    Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
    PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN; Witjes H; Gordon K; Mannaerts B;
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
    Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of different starting doses of FSH on laboratory and clinical outcomes in patients with moderate AMH level.
    Liu M; Wang C; He L; Pan X; Wu C; Pu X; Pan X
    Hormones (Athens); 2024 Jun; 23(2):331-338. PubMed ID: 38342850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?
    Patrelli TS; Gizzo S; Sianesi N; Levati L; Pezzuto A; Ferrari B; Bacchi Modena A
    PLoS One; 2012; 7(9):e44571. PubMed ID: 22984527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
    Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ovarian reserve markers in prediction of clinical pregnancy.
    Zebitay AG; Cetin O; Verit FF; Keskin S; Sakar MN; Karahuseyinoglu S; Ilhan G; Sahmay S
    J Obstet Gynaecol; 2017 May; 37(4):492-497. PubMed ID: 28421902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients.
    Xi W; Gong F; Lu G
    J Assist Reprod Genet; 2012 May; 29(5):397-402. PubMed ID: 22382641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.
    Merhi Z; Zapantis A; Berger DS; Jindal SK
    J Assist Reprod Genet; 2013 Oct; 30(10):1361-5. PubMed ID: 23963620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.